CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Sandler Reiterates Bullish View on CRISPR Therapeutics (CRSP) Amid New Manufacturing Facility
June 29, 2020 8:59 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $104.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) citing a new manufacturing facility to produce cell therapies for clinical and commercial use, the hiring of up to 100 more full-time employees, Car-T advancing, and AACR II showing superior features of Allo Car-T Pipeline.
The... More
